PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF”, “PRF Technologies” or the “Company”) today issued a Letter to Shareholders from Efraim Cohen-Arazi, Interim Chief Executive Officer.

First-Half 2026 and Recent Highlights: * Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet * LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K * Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark * DeepSolar validated its Predict™ platform with real-world European market data, expanded the platform with Battery-to-Revenue Intelligence, joined the NVIDIA Connect program and will showcase GridFeed™ at Energy Trading Week Europe 2026 Dear Fellow Shareholders,